Pioneering perspectives
Prof. Misty Jenkins, Walter and Eliza Hall Institute, Australia
Pioneering perspectives
“If we really want to democratize access to clinical trials...we have to have point-of-care (PoC) manufacturing.”
Prof. Misty Jenkins, Walter and Eliza Hall Institute, Australia
Further discussion
Revolutionizing brain cancer treatment: the promise of personalized immunotherapy
Brain cancer remains one of the most challenging diseases to treat with therapeutic options bearing limitations and poor survival rates.1,2 However, advancements in immunotherapy are opening new doors for patients with this devastating disease.2,3 In a recent interview, Professor Misty Jenkins, Laboratory Head and Co-Director of the Brain Cancer Centre at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia, shared her insights on the future of brain cancer treatment and the role personalized medicine could have in tackling this disease.
As Prof. Jenkins notes early in her interview, "These are a cohort of patients who have no other options". With traditional treatments for such a fast moving cancer, those like radiotherapy and alkylating chemotherapy, offering little success, the urgency to develop new, effective solutions is critical.4
Immunotherapy, specifically CAR T cell therapy, has shown promising results in targeting solid tumors, inclusive of brain cancer.5,6 "Looking at the clinical trial outcomes of both adults and kids with brain cancer, there have been incredibly amazing tumor regressions seen…for CAR T cell therapy at the moment.”
Point-of-care (PoC) cell manufacturing, a decentralized approach where cell therapies are produced locally at or near hospitals, shifts the paradigm of life-saving interventions being traditionally bound by supply chains to one that enables faster and further access to treatments.7,8 Through this decentralized production, hospitals and research centers have the opportunity to create personalized therapies tailored to individual patients, significantly reducing the time between diagnosis and treatment. “If we really want to democratize access to clinical trials…we have to have point-of-care. This will enable us…when that patient walks in that ED, and has a seizure, and that MRI diagnoses with a brain cancer, we can immediately be taking blood and starting manufacture, in a bespoke, personalized way that's specific for that tumor.”
An automated and customizable solution, the CliniMACS Prodigy® Platform, for seamless cell manufacturing, coupled with the MACSQuant® Analyzer 16, for robust analytics, streamlines cell manufacturing – minimizing vein-to-vein time and standardizing manufacturing processes. This standardization and automation ensures reproducibility of cell products across a multitude of locations, further supporting patient access to therapies. “I think the CliniMACS Prodigy Platform enables us to really scale these little lab factories around the country, easily, and tech transfer, easily, across a large geographical location and then hopefully internationally.”
While brain cancer remains one of the most challenging diseases, efforts continue to tackle complex characteristics such as tumor heterogeneity, the tumor microenvironment, and structural brain barriers.9,10,11 Yet, it is with innovative strategies and technologies, such as PoC manufacturing with the CliniMACS Prodigy Platform, that we can drastically impact the time-bound urgency of new patient therapies.
With the goal of understanding how potential immunotherapies, like CAR T cell therapy, could fit into the urgency of solving brain cancer, Prof. Jenkins highlights, “I think that cell therapy will be a piece of the puzzle. It won't solve all the problems, but it will be a piece of the puzzle that we can then combine with other therapies to really combat that problem from different angles. We have to try, we can't talk about five-year survival rates, for a three year old – we have to talk about cure.”
"We have to try, we can't talk about five-year survival rates, for a three year old – we have to talk about cure.”
Prof. Misty Jenkins, Walter and Eliza Hall Institute, Australia
Watch more interviews
You have previously chosen International as your location.
What do you want to do?